The four TCGA molecular profiles (e.g., POLE-mutated, p53-abnormal) have evolved beyond predicting outcomes to actively guiding treatment, such as de-escalating therapy for low-risk groups and escalating for high-risk ones.

When a patient has both ESR1 and PIK3CA pathway mutations, the choice between an oral SERD and a PI3K/AKT inhibitor is not straightforward. For patients with a low tumor burden and endocrine-sensitive disease, a better-tolerated single-agent oral SERD is preferred. For those with a higher disease burden, the more aggressive combination therapy is warranted.

When considering escalating therapy for a patient with a high-risk p53 mutation, clinicians are adopting a key checkpoint: confirming the absence of a concurrent POLE mutation. The presence of a POLE mutation is thought to mitigate the aggressiveness of p53-mutated tumors, potentially making treatment escalation unnecessary.

The RUBY trial surprisingly revealed that patients with p53-mutated tumors, a subset of the generally less responsive pMMR group, derive significant benefit from adding immunotherapy to chemotherapy, challenging previous assumptions about this molecular subtype.

Features like brain metastases or p53 co-mutations are considered high-risk. However, about 75% of patients have at least one such factor, making the "high-risk" profile the norm, not the exception, and reinforcing the need for upfront combination therapy.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

The Victoria 1 study showed that adding a CDK4/6 inhibitor (triplet therapy) improved outcomes only in patients with PIK3CA wild-type tumors. In PIK3CA-mutant tumors, the doublet therapy was equally effective. This surprising finding highlights that distinct resistance mechanisms are at play and that mutation status is critical for selecting optimal combination regimens.

While adding venetoclax to a hypomethylating agent is standard for many AML patients, it is not recommended for those with P53 mutations. Despite potentially higher initial response rates, the combination does not translate into improved overall survival for this specific genetic subset, making it an ineffective long-term strategy.

TP53-mutated AML carries an extremely poor prognosis, significantly worse than other adverse-risk subtypes. When TP53 patients are excluded from analyses, the survival gap between the remaining adverse-risk and intermediate-risk patients narrows considerably, clarifying risk stratification.